ALUR
Allurion Technologies Inc. focuses on ending obesity with a weight loss platform to treat people who are overweight. Its platform, the Allurion Program, features swallowable and procedure-less intragastric balloon for weight loss (the Allurion Balloon) and offers access to AI-powered remote patient monitoring tools, a proprietary behavior change program, secure messaging, and video telehealth that are delivered by the Allurion Virtual Care Suite. The company is headquartered in Natick, Massachusetts.
Allurion Technologies, Inc. (ALUR) is rated C (2.2/5) on Deltasharpe Prism, scored against Healthcare sector peers. Its strongest pillar is Profitability (C+); its weakest is Growth (D-).
Quantitative Factor Evaluation • Updated
Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms
Ratings of B- and above are for members.
Register free to see every rating — your first 2 weeks of Premium are on us.
Register — 2 weeks freeUnderlying Financial Metrics
Historical Factor Score Progression
| Date | Value | Growth | Profitability | Momentum | Revisions | Overall |
|---|---|---|---|---|---|---|
| 2026-08-05 | C+ (2.7) | D- (1.1) | C+ (2.8) | C (2.4) | C- (1.9) | C (2.2) |
| 2026-08-04 | C+ (2.7) | D- (1.1) | C+ (2.8) | C (2.4) | C- (1.9) | C (2.2) |
| 2026-08-03 | C+ (2.7) | C- (2.1) | B- (3.0) | C (2.4) | C- (2.0) | C (2.4) |
| 2026-08-02 | C+ (2.7) | C- (2.1) | B- (2.9) | C (2.4) | C- (1.9) | C (2.4) |